Bethanecol chloride for treatment of clomipramine-induced orgasmic dysfunction in males

Authors

  • Márcio Bernik University of São Paulo; Faculty of Medicine; Hospital das Clínicas; Department of Psychiatry
  • Antonio Hélio Guerra Vieira University of São Paulo; Faculty of Medicine; Hospital das Clínicas; Department of Psychiatry
  • Paula Villela Nunes University of São Paulo; Faculty of Medicine; Hospital das Clínicas; Department of Psychiatry

DOI:

https://doi.org/10.1590/S0041-87812004000600008

Keywords:

Orgasmic dysfunction, Clomipramine, Bethanecol chloride, Panic disorder, Pharmacological treatment

Abstract

PURPOSE: To investigate whether bethanecol chloride may be an alternative for the clinical management of clomipramine-induced orgasmic dysfunction, reported to occur in up to 96% of male users. METHODS: In this study, 12 fully remitted panic disorder patients, complaining of severe clomipramine-induced ejaculatory delay, were randomly assigned to either bethanecol chloride tablets (20 mg, as needed) or placebo in a randomized, double-blind, placebo-controlled, two-period crossover study. A visual analog scale was used to assess severity of the orgasmic dysfunction. RESULTS: A clear improvement was observed in the active treatment period. No placebo or carry-over effects were observed. CONCLUSION: These findings suggest that bethanecol chloride given 45 minutes before sexual intercourse may be useful for clomipramine-induced orgasmic dysfunction in males.

Downloads

Published

2004-01-01

Issue

Vol. 59 No. 6 (2004)

Section

Original Research

How to Cite

Bernik, M., Vieira, A. H. G., & Nunes, P. V. (2004). Bethanecol chloride for treatment of clomipramine-induced orgasmic dysfunction in males . Revista Do Hospital Das Clínicas, 59(6), 357-360. https://doi.org/10.1590/S0041-87812004000600008